NASDAQ:RNA Avidity Biosciences - RNA News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $20.09 +0.31 (+1.57%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$19.68▼$20.2850-Day Range$19.56▼$25.6552-Week Range$9.83▼$25.74Volume471,360 shsAverage Volume1.07 million shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$44.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼1.270.61▲Average Medical News Sentiment RNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼21▲RNA Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAvidity Biosciences (NASDAQ:RNA) Shares Down 3.6% americanbankingnews.com - March 24 at 8:48 AMAvidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conferencefinance.yahoo.com - March 13 at 7:41 PMAvidity Biosciences: Helping Deliver Oligonucleotides Outside Liver Cellsseekingalpha.com - March 11 at 5:21 PMAvidity Biosciences (RNA) Receives a Buy from Credit Suissemarkets.businessinsider.com - March 1 at 2:32 PMAvidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlightsfinanznachrichten.de - March 1 at 9:31 AMAvidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlightsfinance.yahoo.com - March 1 at 9:31 AMAvidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimatesfinance.yahoo.com - March 1 at 9:31 AMAnalyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stockfinance.yahoo.com - February 27 at 5:05 PMAvidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platformfinance.yahoo.com - February 27 at 10:55 AMAvidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leaderfinance.yahoo.com - February 23 at 9:08 AMAvidity's AOC 1020 Gets FDA Orphan Drug Designation For Muscular Dystrophy Treatmentmarkets.businessinsider.com - February 14 at 1:36 PMAvidity Biosciences Gets FDA Orphan Designation for AOC 1020 >RNAmarketwatch.com - February 14 at 1:36 PMAvidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophyfinance.yahoo.com - February 14 at 1:36 PMAvidity Biosciences to Participate in Upcoming Investor Conferencefinance.yahoo.com - February 7 at 9:16 AMThe one-year returns have been notable for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasingfinance.yahoo.com - February 2 at 10:19 AMAvidity's therapy for rare muscle disorder gets FDA fast track statusmsn.com - January 18 at 2:54 PMAvidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophyfinance.yahoo.com - January 18 at 9:54 AMPeering Into Avidity Biosciences's Recent Short Interestmsn.com - January 3 at 1:26 PMAvidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeuticsseekingalpha.com - December 23 at 8:30 AMFollowing a 16% decline over last year, recent gains may please Avidity Biosciences, Inc. (NASDAQ:RNA) institutional ownersfinance.yahoo.com - December 23 at 8:30 AMAvidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technologyseekingalpha.com - December 22 at 6:55 AMAvidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platformseekingalpha.com - December 21 at 6:49 AMThis Genetic Medicine Stock Soared Over 50% on Industry Firstmsn.com - December 15 at 3:21 PMThis Genetic Medicine Stock Soars Over 50% on Industry Firstfinance.yahoo.com - December 14 at 11:37 PMAvidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trialfinance.yahoo.com - December 14 at 6:37 PMExpert Ratings for Avidity Biosciencesmarkets.businessinsider.com - December 14 at 6:37 PMHow A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratospherefinance.yahoo.com - December 14 at 1:36 PMAvidity Reports Effective Delivery Of SiRNA Into Muscle; Shows Meaningful DMPK Reductionmarkets.businessinsider.com - December 14 at 8:36 AMAvidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeuticsfinance.yahoo.com - December 14 at 8:36 AMAvidity's stock rallies 39% on new RNA datafinance.yahoo.com - December 14 at 8:36 AMRNA Sequencing Analysis Market : Competitive Landscape and Analysis by Recent Trends 2023 to 2028marketwatch.com - December 13 at 6:16 AMDown 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)finance.yahoo.com - November 18 at 1:29 PMAvidity Biosciences Third Quarter 2022 Earnings: Beats Expectationsfinance.yahoo.com - November 11 at 9:47 AMAvidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlightsfinance.yahoo.com - November 8 at 4:23 PMAvidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skippingfinance.yahoo.com - October 11 at 9:02 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNAbenzinga.com - October 6 at 7:15 PMAvidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Societyfinance.yahoo.com - October 6 at 2:15 PMAvidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophyfinance.yahoo.com - September 29 at 10:23 AMU.S. FDA puts Avidity's muscle disorder drug trial on partial holdmsn.com - September 28 at 2:57 AMFDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trialfinance.yahoo.com - September 27 at 4:56 PMAvidity: FDA Places Partial Clinical Hold On Participant Enrollment In Phase 1/2 MARINA Trialnasdaq.com - September 27 at 11:55 AMTwitter, JetBlue, Lucid Group Rise Premarket; Avidity, Ferguson Fallmsn.com - September 27 at 11:55 AMU.S. FDA puts Avidity's muscle disorder drug study on holdmsn.com - September 27 at 11:55 AMAvidity Biosciences: FDA Places Partial Hold on AOC 1001 Study >RNAmarketwatch.com - September 27 at 11:55 AMAvidity Biosciences Shares Slide on Partial FDA Study Hold >RNAmarketwatch.com - September 27 at 11:55 AMAvidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trialfinance.yahoo.com - September 27 at 11:55 AMAvidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trialfinance.yahoo.com - September 27 at 11:55 AMHighly Rated Avidity Biosciences Hammered After Side Effect Sidelines Studyfinance.yahoo.com - September 27 at 11:55 AMAvidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programsfinance.yahoo.com - September 7 at 8:11 AMThe one-year returns have been for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasingnasdaq.com - August 20 at 11:12 PM Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:RNA) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.